Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 36 of 1,261
  1. US 12331297

    Coagulation factor V (F5) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  2. US 12331107

    Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

    AVALO THERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  3. US 12331109

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  4. US 12331110

    Monoclonal antibodies against endotrophin and the use thereof

    The Board of Regents of the University of Texas System · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  5. US 12331124

    ALK2 antibodies and methods of use thereof

    Keros Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  6. US 12331105

    Broadly neutralizing antibodies against HIV

    United States Government as represented by the Department of Veterans Affairs · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  7. US 12329776

    Treatment methods for ALS patients

    The Regents of the University of California · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  8. US 12331130

    DDR1 antibodies and uses thereof

    The Board of Regents of the University of Texas System · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  9. US 12331328

    CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome

    Editas Medicine, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  10. US 12332255

    Methods for monitoring treatment of chronic liver disease

    The Regents of the University of Colorado · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  11. US 12329739

    Isoflavonoid compounds and methods for the treatment of cancer

    Aardvark Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  12. US 12331132

    Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses

    Inhibrx Biosciences, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  13. US 12331334

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Vertex Pharmaceuticals Incorporated · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  14. US 12331279

    Systems for producing cellular immunotherapeutics and methods of use thereof

    Northwestern University · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  15. US 12331293

    Bispecific antisense oligonucleotides for dystrophin exon skipping

    BIOMARIN TECHNOLOGIES B.V. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  16. US 12329747

    Use of lipophilic beta-lactam antibiotics and carboxylate esters for the treatment of bacterial infections within citrus and other plant species

    Board of Regents of the Nevada System of Higher Education on behalf of Nevada State College · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  17. US 12329748

    Anhydrous compositions of mTOR inhibitors and methods of use

    PALVELLA THERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  18. US 12329751

    Topical roflumilast formulation having antifungal properties

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  19. TW 202523278

    Antibody drug conjugate platforms

    BEIGENE LTD [KY] · Granted Jun 16, 2025 · Expires Jun 11, 2045

    granted
  20. WO 2025121445

    POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2

    ASTELLAS PHARMA INC [JP] · Granted Jun 12, 2025 · Expires Jun 7, 2045

    granted
  21. WO 2025120866

    POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET AGENTS STABILISANT OU AUGMENTANT L'EXPRESSION DE CLDN18.2

    ASTELLAS PHARMA INC [JP] · Granted Jun 12, 2025 · Expires Jun 7, 2045

    granted
  22. WO 2025120867

    POLYTHÉRAPIE IMPLIQUANT DES AGENTS DE LIAISON BISPÉCIFIQUES SE LIANT À CLDN18.2 ET CD3 ET ANTICORPS ANTI-VEGFR2

    ASTELLAS PHARMA INC [JP] · Granted Jun 12, 2025 · Expires Jun 7, 2045

    granted
  23. AR 132316

    TRATAMIENTO COMBINADO CON CLASCOTERONA Y MINOXIDIL

    CASSIOPEA S P A [IT] · Granted Jun 11, 2025 · Expires Jun 6, 2045

    granted
  24. EP 4567716

    ERZEUGUNG SYNTHETISCHER DARSTELLUNGEN

    BAYER AG [DE] · Granted Jun 11, 2025 · Expires Jun 6, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.